VTS-270 for treating Niemann-Pick type C1 (ID1267)
Proposed [GID-HST10020] Expected publication date: TBC
Search results
661 results
-
-
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
Proposed [GID-HST10034] Expected publication date: TBC
-
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Proposed [GID-HST10019] Expected publication date: TBC
-
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Proposed [GID-HST10022] Expected publication date: TBC
-
Avalglucosidase alfa for treating Pompe disease [ID3737]
Proposed [GID-HST10030] Expected publication date: TBC
-
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Proposed [GID-HST10037] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Proposed [GID-HST10039] Expected publication date: TBC
-
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]
Proposed [GID-HST10043] Expected publication date: TBC
-
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]
Proposed [GID-HST10038] Expected publication date: TBC
-
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818
Proposed [GID-HST10040] Expected publication date: TBC
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 05 March 2021.
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 05 March 2021.
-
Sapropterin for treating phenylketonuria [ID1475]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 18 March 2021.
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 04 March 2021.
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Givosiran for treating acute hepatic porphyria [ID1549]
In development [GID-HST10035] Expected publication date: TBC
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: 13 August 2021
-
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]
In development [GID-HST10027] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
In development [GID-HST10032] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: TBC
-
Vaccine uptake in the general population
In development [GID-NG10139] Expected publication date: 06 April 2022
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 09 February 2022
-
Mental wellbeing at work
In development [GID-NG10140] Expected publication date: 15 December 2021
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 17 May 2022
-
Looked-after children and young people
In development [GID-NG10121] Expected publication date: 27 September 2021
-
Tobacco: preventing uptake, promoting quitting and treating dependence (update)
In development [GID-NG10086] Expected publication date: 01 September 2021
-
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]
In development [GID-TA10562] Expected publication date: 03 March 2021
-
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]
In development [GID-TAG430] Expected publication date: 03 March 2021
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Proposed [GID-TA10637] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Proposed [GID-TA10638] Expected publication date: TBC
-
Remdesivir for treating COVID-19 [ID3808]
Proposed [GID-TA10721] Expected publication date: TBC
-
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Proposed [GID-TA10599] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Proposed [GID-TA10604] Expected publication date: TBC
-
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)
Proposed [GID-TA10279] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Proposed [GID-TA10346] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Proposed [GID-TA10298] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Proposed [GID-TA10716] Expected publication date: TBC
-
Mepolizumab for treating hypereosinophilic syndrome [ID3749]
Proposed [GID-TA10755] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]
Proposed [GID-TA10781] Expected publication date: 22 September 2021
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Proposed [GID-TA10723] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Proposed [GID-TA10726] Expected publication date: TBC
-
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Proposed [GID-TA10431] Expected publication date: TBC
-
Dapagliflozin for treating chronic kidney disease [ID3866]
Proposed [GID-TA10808] Expected publication date: TBC